Google
CSTL Stock Analysis — CASTLE BIOSCIENCES INC (Healthcare >> Diagnostics & Research)
CSTL FAQ
What is CSTL's P/E ratio?
CASTLE BIOSCIENCES INC (CSTL) currently trades at a P/E ratio of 179.65.
What is CSTL's ROE?
CASTLE BIOSCIENCES INC reports a Return on Equity (ROE) of -2.78%.
What is CSTL's dividend yield?
CASTLE BIOSCIENCES INC offers a dividend yield of 0.00%.
What is CSTL's Quality Score?
Our AI rates CSTL's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CSTL?
Our AI Timing Score for CSTL is 96 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CSTL belong to?
CASTLE BIOSCIENCES INC is classified under the Healthcare >> Diagnostics & Research sector on the NASDAQ exchange
CSTL AI Analysis Summary
Our AI summary for CSTL: CASTLE BIOSCIENCES INC (NASDAQ), Healthcare >> Diagnostics & Research sector. The stock currently trades at a P/E of 179.65, ROE of -2.78%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 96/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 28.00
Price
1.21
(4.52%)
Day Change
|
|
|---|
CSTL, the overall quality is not good ( Quality = 15) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 28.00 |
| PBV / Sector |
1.76 / -29.69
|
| Earning Per Share | -0.44 |
| PE / Sector |
179.65 / 48.18
|
| PEG or PE/Growth / Sector |
-1.42 / 1.64
|
| Average 1M Daily Value |
9.70 M
|
| Average 1W Daily Value |
17.92 M
GREAT
|
| Timing Factors |
|
100% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 07:59:41 |
| Symbol | CSTL |
| Name | CASTLE BIOSCIENCES INC |
| Sector | Healthcare >> Diagnostics & Research |
| Market | NASDAQ |
| Listed Shares | 30.33 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 812.54 / 38,081.42 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1500 W. Parkwood Ave, Friendswood, TX, United States, 77546
Phone: 866 788 9007
Website: https://castlebiosciences.com
Employees: 942
Description: Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Diagnostics & Research
Click a bubble to view stock details · Bubble size represents market capitalization share
